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to that of the 12 patients who had pretransplant splenectomy 
(91.6 ± 7.9% and 66.1 ± 13.8% respectively). Posttransplant 
splenectomy produced the desired effects in all 11 patients in 
that the leukopenia was permanently reversed, significantly 
higher doses of cytotoxic drugs were tolerated, and serum 
creatinine levels declined. Although the numbers are small, this 
preliminary study is encouraging and indicates that selective 
posttransplant splenectomy may be a reasonable alternative to 
routine prophylactic pretransplant splenectomy in recipients 
of cadaveric renal allografts. 
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@ PERIPHERAL BLOOD T LYMPHOCYTES fOUND IN RENAL ALLOGRAFT RECIPIENTS TREATED WITH 
CYCLOSPORINE1 
Improved allograft survival has been observed in patien~ I intravenous pyelogram (lVP). Rejection was treated with an 
treated with cyclosporine, a new immunosuppressive agent (1, _. Lv. bolus of 1 g hydrocortisone, graft irradiation, and an in-
2). One problem in the management of patients treated with crease in the oral prednisone to 200 mg on the first day, tapered 
cyc\osporine is a drug-associated nephrotoxicity (2,3) that can to a 20-mg maintenance dose over the next five days. Cyclo-
be difficult to distinguish from rejection. Recently, it has been sporine toxicity, which clinically appears similar to rejection 
noted that changes in T lymphocyte subpopulations in the with a rising serum creatinine, was suspected when urine output 
peripheral blood may indicate rejection in renal allograft recip- was maintained (1.5-2 L/day), the patient felt well, and renal 
ients immunosuppressed with azathioprine, steroids, and anti- flow studies were normal or nearly normal. Cyclosporine tox-
lymphocyte serum (ALS) (4,5). To evaluate this technique for icity was presumed when the patient failed to respond to 
its application in detecting rejection episodes and to see if radiation and increased steroid treatment but did respond with 
specific changes in the T cell subpopulations OCCUI that may a decrease in serum creatinine when the cyc\osporine dose was 
account for the immunosuppressive properties of cyclosporine diminished. 
early in the post transplant period, we followed the peripheral Of the 20 transplanted kidneys with cyclosporine treatment, 
blood T lymphocyte subpopulations sequentially after trans- four were lost; two kidneys were rejected despite immuno· 
plantation in cadaveric renal allograft recipients treated with suppression; one kidney was lost when a patient with good 
cyclosporine. renal function died of myocardial infarction; and one kidney 
Samples of blood were taken from 59 uremic patients visiting was lost to rejection when immunosuppression was discontin-
the Urology Clinic for transplant evaluation, and from 20 ued because of medical complications. 
patients at intervals before and after cadaveric renal transplan- Automated leukocyte counts were performed on the blood 
tation. The twenty transplant recipients received cyclosporine samples using a Coulter Counter (Coulter Electronics, Inc., 
(Sandoz) at a dose of 17.5 mg/kg by mouth 5 hr before trans- Hialeah, FL) and a differential blood count was obtained man-
plantation, along with intravenous administration of 1 g of ually from smears stained with Wright's stain. The absolute 
methylprednisolone. The cyclosporine was given daily postop- number of lymphocytes was calculated from the leukoc}te count 
eratively and the dose was tapered to 10-12 mg/kg from 2 and the percentage of lymphocytes. Lymphocytes were sepa-
weeks to 2 months after the operation, depending on the serum rated from the blood sa'mples on a Ficoll-Hypaque gradient and 
creatinine. Oral prednisone was begun at 200 mg on the first aliquots of the cells were treated with fluorescein isothiocya-
postoperative day and tapered over the next 5 days to a main- nate-conjugated monoclonal antibodies Leu 4 (reacting wit h 
tenance dose of 20 mg. the total T lymphocyte population), Leu 2a (reacting with the 
Rejection was diagnosed when serum creatinine rose at least T cytotoxic/suppressor population), or Leu 3a (reacting with 
0.5 mg/l00"rn1 over baseline, together with a decrease in the the T helper population; Becton-Dickinson, Mountain View, 
urine output and the appearance of graft tenderness. In addi- CAl (6). The cells were washed, and the fluorescent populations 
tion, other causes of the decreased renal function were excluded were counted using the fluorescence-activated cell sorter (FACS 
by physical examination, ultrasound, renal flow studies, and IV, Becton·Dickinson, Mountain View, CAl. The lymphocyte 
I Presented at the Annual Meeting of the American Society of 
Transplant Surgeons, Chicago, IL, June 3--4, 1982. Supported in part 
by research funds from the Division of.L'rological Surgery, Ol'partment 
of Surgery, University of Pittsburgh School of Medicine, and by Re-
search Funds (rom the Veteran's Administration. 
suhpopulation was expressed as a percentage of the total num-
ber of lymphocj1es. The helper/suppressor ratio (H/S) was 
calculated by dividing the percentage of Leu-3a-positive cells 
by the percentage of Leu·2a-positive cells. The values were 
compared statistically using the nonparametric Mann- Whitney 
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U and Kruskal-Wallis tests. Approximately 70% of the lym-
phocytes from normal subjects were Leu-4-positive; 50% re-
acted with Leu 3a, and 20);, with Leu 2a. The normal H/S ratio 
ranged from 1.1 to 2.0. 
The 59 uremic patients had normal values for the lymphocyte 
subpopulations studied (Table 1). No statistical difference was 
observed between values obtained from male and female pa-
tients, as had been reported (7,8). 
Blood samples were taken from renal allograft recipients 
preoperatively, within the first 24 hr, and then at weekly 
intervals up to four months following transplantation. Al-
though a sharp decrease in the absolute numbers of lympho-
cytes was observed immediately after transplantation in cyclo-
sporine-treated patients, this value rebounded to nearly normal 
levels by one week after transplantation (Table 2). The periph-
eral blood T lymphocyte subpopulations were determined daily 
in two cyclosporine-treated patients for the first week after 
transplantation, and the values showed a drop in the number 
of lymphocytes on the first postoperative day, followed by 
gradual recovery to normal values at one week postoperatively 
(data not shown). The lower number of lymphocytes in the 
peripheral blood of cyclosporine-treated patients may be due to 
the high initial steroid dosage that was diminished early in 
these patients. 
A comparison between lymphocyte population values ob-
tained from cyclosporine-immunosuppressed patients with 
good renal function and from those with various disturbances 
in renal function is shown in Table 3. The absolute number of 
blood lymphocytes and the percentage of the cytotoxic/sup-
pressor subpopulation (Leu-2a-positive lymphocytes) were sig-
TABLE 1. Peripheral blood T lymphocyte subpopulations in uremic patients 
Patients N Lymphocytes· Total T cells" SUP/CYT T Cells· Helper T cells" HIS ratio' 
Male 36 21 (1472 ± 618) 65 (983 ± 506) 23 (364 ± 271) 44 (664 ± 389) 2.2 (0.4-4.1) 
Female 23 22 (1510 ± 694) 71 (1095 ± 552) 27 (412 ± 249) 46 (694 ± 375) 2.1 (0.6-5.2) 
Total 59 22 (1487 ± 643) 68 (1026 ± 523) 24 (383 ± 262) 44 (676 ± 381) 2_2 (0.4-5.2) 
• The first number is the percentage of the leukocytes; the number in parentheses is the mean absolute cell count/mm3 ± one standard 
deviation. 
b Leu-4-positive lymphocytes; the first number is the percentage of positive lymphocytes; the number in parentheses is the mean absolute cell 
count/mm' ± one standard deviation. 
, Leu-2a-positive lymphocytes. 
d Leu-3a-positive lymphocytes. 
• The numbers in parentheses are the range. 
TABLE 2. Peripheral blood T lymphocyte subpopulations in cyclosporine-treated renal allograft recipients 
Time N Lymphocytes' Total T cells" SUP/CYT T Cells~ Helper T cells'" 
Preoperative 9 30 (1872 ± 605) 66 (1259 ± 475) 25 (482 ± 317) 39 (731 ± 335) 
Postoperative 20 9 (756 ± 469) 45 (335 ± 252) 20 (153 ± 104) 30 (241 ± 192) 
1 Week 12 18 (2297 ± 1448) 53 (1327 ± 1036) 17 (403 ± 283) 37 (911 ± 671) 
2 Weeks 15 19 (1887 ± 1031) 57 (1157 ± 839) 19 (391 ± 287) 38 (737 ± 602) 
3 Weeks 8 18 (1335 ± 1210) 56 (825 ± 9231 1 22 (293 ± 256) 29 (316 ± 160) 
4 Weeks 8 25 (1576 ± 1058) 57 (1028 ± 992) 26 (420 ± 456) 38 (694 ± 690) 
2 Months 14 17 (1205 ± 741) 70 (841 ± 576) 27 (312 ± 200) 42 (511 ± 364) 
3 Months 3 21 (1231 ± 1227) 81 (978 ± 925) .25 (314 ± 168) 52 (644 ± 636) 
4 Months 6 24 (1974 ± 1031) 77 (1384 ± 800) 28 (538 ± 413) 43 (727 ± 360) 
HIS ratio' 
1.3 (0.6-2.0) 








• Number is the percentage of the leukocytes; the number in parentheses is the mean absolute number of cells, ± one standard deviation. 
• Leu-4-positive lymphocytes; the first number is the percentage of positive lymphocytes; the number in parentheses is the mean absolute cell 
count/mm' ± one standard deviation. 
• Leu-2a-positive lymphocytes. 
4 Leu-3a-positive lymphocytes. 
• Numbers in parentheses are the range. 
TABLE 3. Peripheral blood T lymphocyte subpopulations in cyclosporine-treated patients compared by graft status 
Graft No. No. Lymphocytes' Total T cells" SUPICUT cells~ Helper cells" HIS ratio' status Patients Observation. 
Good 20 61 19 (1606 ± 1155) 63 (1071 ± 831) 24 (378± 294) 39 (652 ± 526) 1.9 (0.3-4.4) 
Rejection 3 10 13 (905 ± 412>' 42 (337 ± 186>' 14' (116 ± 67>' 32 (267 ± 134>' 2.5 (0.7-2.9) 
ATN 8 13 12 (688 ± 816) 43 (1441 ± 1179) 18 (265 ± 264) 27 (442 ± 545) 1.6 (1-1.7) 
Cyclosporine 2 2 10 (481 ± 70) 58 (282 ± 57) 32 (149 ± 69) 39 (186 ± 16) 1.4 (1-1.7) 
Toxicity 
• The first tfumber is the percentage of the leukocytes; the number in parentheses is the mean absolute number of cells ± one standard 
deviation. 
• Leu-4-positive lymphocytes; the first number is the percentage of positive lymphocytes; the number in parentheses is the mean absolute cell 
count/mm' ± one standard deviation. 
• Leu-2a-positive lymphocytes. 
4 Leu-3a-positive lymphocytes. 
• The numbers in parentheses are the range. 
'Significantly different (P < 0.05) from values during good graft function. 
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nificantly lower in samples taken during rejection. Although 
the number of observations is small, the lower absolute lym-
phocyte count and percentage of the cytotoxic/suppressor sub-
population may be a result of the increased steroid therapy 
given these patients. Too few observations during cyclosporine 
toxicity were made for a useful statistical comparison. No 
correlation was observed between rejection and any of the other 
values, including the H/S ratio. 
Cyclosporine has profound immunosuppressive effects, but 
the mechanism of its action is not known (1). Cyclosporine has 
been reported to spare suppressor T lymphocyte subpopulations 
and to prevent the secretion of, or response to, interleukin 2 
(9-11). In this study, we found no specific changes in T lym-
phocyte subpopulations in response to immunosuppression 
with cyclosporine. These results may indicate that cyclosporine 
immunosuppression causes functional changes in lymphocytes 
that are not reflected by numerical alteration in the peripheral 
blood, or that the population changes occurring during cyclo-
sporine therapy were too subtle to be detected with the methods 
we used. Other antisera reacting with specific functional sub-
populations of T lymphocytes are currently under investigation 
(12) and these may prove more useful in following patients 
treated with cyclosporine. The significantly lower percentage 
of Leu-2a-positive lymphocytes observed in the cyclosporine-
treated patients during rejection may indicate the response to 
increased steroid therapy. These changes are statistically sig-
nificant, but they are not useful in monitoring individual pa-
tients because there is great individual variation and overlap 
with results from other patient populations (Table 3). 
These results differ from those of other reports that have 
shown specific changes in peripheral blood T lymphocyte sub-
populations during rejection in azathioprine, steroid, and ALS-
immunosuppressed patients (4,5). Sweny and Tidman exam-
ined peripheral blood T lymphocyte subpopulations in patients 
treated with cyclosporine alone; they observed a specific in-
crease in the T suppressor/cytotoxic subpopulation in patients 
after more than two months of cyc\osporine immunosuppres-
sion, but not early in treatment with cyc\osporine alone or in 
treatment with cyclosporine 'plus prednisolone (13). However, 
Morris et aI., in a study of patients treated with cyc\osporine 
alone from 4-8 weeks following transplantation, did not report 
an increase in the suppressor population, and found no corre-
lation with rejection and changes in the H/S ratio (14). Differ-
ences in the immunosuppressive protocol may affect the obser-
vations, especially in the combined use of ALS with azathio-
prine and steroids (4,5), in the use of steroids with cyc\osporine 
(13); the time of sampling (J 3) or the presence of viral or fungal 
infections (15) may also have an effect. Thus, further work in 
this area is necessary. However, in this study, the determination 
of peripheral blood T lymphocyte subpopulations was not help-
ful in det.ecting rejection or in discriminating between rejection 
and cyc\osporine toxicity. 
MONICA LIEBERTl 
J. THOMAS ROSENTHALl 
, 
1 VA Medical Center, Pittsburgh; and Division of Urological Sur-
gery, Department of Surgery, University of Pittsburgh School of Med-
icine. 
EDWARD MERRALL2 
RODNEY J. TAYLOa1 
GURMUKH SINGH2 
THOMAS E. STARZL3 
BRUCE S. RABIN2 
THOMAS R. HAKALAl 
VA Medical Center, Pittsburgh • 
University of Pittsburgh School of Medicine 
Pittsburgh, Pennsylvania 15261 
LITERATURE CITED 
1. Morris PJ. Cyc\osporin A. Transplantation 1981; 32: 349. 
2. Caine RY, Rolles K, White DJG, et al. Cyc\osporin A initially as 
the only immunosuppressant in 34 recipients of cadaveric organs: 
32 kidneys, 2 pancreases and 2 livers. Lancet 1979; 2: 1033. 
3. Klintmalm GBG, Iwatsuki S, StanJ TE. Nephrotoxicity of Cyclo-
sporin A in liver and kidney transplant patients. Lancet 1981; 1: 
470. 
4. Ellis TM, Berry CR, Mendez-Picon G, et al. Immunological mon-
itoring of renal allograft recipients using monoclonal antibodies 
to human T lymphocyte suhpopulations. Transplantation 1982; 
33: 317. 
5. Cosimi AB, Colvin RB, Burton RC, et al: Use of monoclonal 
antibodies to T-cell subsets for immunologic monitoring and 
treatment in recipients of renal allografts. N Engl J Med 1981; 
305: 3OS. 
6. Evans RL, Wall DW, Platsoucas CD, et al. Thymus-dependent 
membrane antigens in man: inhibition of cell-mediated lymphol-
! lysis by monoclonal antibodies to T H2 antigens. Proc Nat! Acad 
Sci USA 1981; 78: 544. 
7. Larsen AE, Mahowald N. Monoclonal antibodies to T-cell subsets 
in renal allograft recipients. N Engl J Med 1981; 305: 1474. 
8. Cosimi AB, Burton RC, Colvin RB, Russell PS: ~plyK N Engl J 
Med 1981; 305: 1474. 
9. Hutchinson IF, Shadur CA, Duarte JSA, Strom TB, Tilney NL. 
Cyclosporin A spares selectively lymphocytes with donor-specific 
suppressor characteristics. Transplantation 1981; 32: 210. 
10. Palacios R, Moller G: Cyclosporin A blocks receptors for HLA-DR 
antigens. Nature 1981; 290: 792. 
11. Bunjes D, Hardt C, Rollinghoff M, Wagner H. Cyclosporin A 
mediates immunosuppression of primary cytotoxic T cell re-
sponses by impairing the release of interleukin 1 and interleukin 
2. Eur J Immunol 1981; 11: 657. 
12. Corte G, Mingar MC. Moretta A, Damiani G, Moretta L, Bargellesi 
A. Human T cell subpopulations defined by a monoclonal anti-
body: I. A small subset is responsible for proliferation to alloge-
neic cells or to antigens and for helper activity for B cell differ-
entiation. J Immunol1982; 128: 16. 
13. Sweny P, Tidman N. The effect of Cyciosporin A on peripheral 
blood T cell subpopulations in renal allografts. Clin Exp Immunol 
1982; 47: 445. 
14. Morris PJ, Carter NP, Cullen PR, Thompson JF, Wood RFM. 
Role of T-cell-subset monitoring in renal·allograft recipients. N 
Engl J Med 1982; 306: 1110. 
15. Flaa C, Fuller L, Kyriakides GK, Miller J. The functional signifi-
cance of T4-T8 cell subsets in kidney transplantation. Fed Proc 
1982; 41: 937. 
Received 16 August 1982. 
Accepted 30 November 1982. 
2 Division of Immunopathology, Department of Pathology, Univer-
sity of Pittsburgh School of Medicine. 
3 V.A. Medical Center, Pittsburgh, and Department of Surgery, Uni-
versity of Pittsburgh School of Medicine. 
